Literature DB >> 17699349

Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations.

James P Ebben1, David T Gilbertson, Robert N Foley, Allan J Collins.   

Abstract

National payment policies target a hemoglobin range of 11 to 12.5 g/dl for patients with ESRD. However, clinical complications and provider practices may contribute to wide fluctuations over time. This study evaluated the frequency with which patients maintain stable hemoglobin levels below, within, and above the Centers for Medicare & Medicaid Services target range and assessed patterns of hemoglobin level change that resulted in large fluctuations across the target range during a 6-mo period. All hemodialysis patients who survived the first 6 mo of 2003, had Medicare as primary payer, and had Medicare outpatient erythropoietin claims in each of the first 6 mo of 2003 (n = 152,846) were studied. Six patient groups were defined on the basis of patterns of hemoglobin level fluctuation: Consistently low (<11 g/dl), consistently target range (11 to 12.5 g/dl), consistently high (> or =12.5 g/dl), low-amplitude fluctuation with low hemoglobin levels, low-amplitude fluctuation with high hemoglobin levels, and high-amplitude fluctuation. Only 10.3% of patients maintained stable hemoglobin levels during the 6 mo and only 6.5% in the target range. The consistently low group had the highest percentage of hospitalizations and the highest number of comorbid conditions. High-amplitude fluctuation was the most common pattern (39.5%), with hemoglobin levels falling below and rising above the target range during the 6-mo period. Hemoglobin levels in almost 90% of patients are in some degree of flux at any point in time, and the fluctuation is highly associated with clinical complications and provider practices.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17699349     DOI: 10.2215/CJN.01110306

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  51 in total

1.  Determinants of hemoglobin variability in stable peritoneal dialysis patients.

Authors:  Hakki Arikan; Ebru Asicioglu; Arzu Velioglu; Serdar Nalcaci; Gurdal Birdal; Derya Guler; Mehmet Koc; Serhan Tuglular; Cetin Ozener
Journal:  Int Urol Nephrol       Date:  2014-04-01       Impact factor: 2.370

2.  The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients.

Authors:  Mana Yahiro; Takahiro Kuragano; Aritoshi Kida; Rie Kitamura; Minoru Furuta; Yukiko Hasuike; Yoshinaga Otaki; Hiroshi Nonoguchi; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2012-01-24       Impact factor: 2.801

Review 3.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  Determining optimum hemoglobin sampling for anemia management from every-treatment data.

Authors:  Adam E Gaweda; Brian H Nathanson; Alfred A Jacobs; George R Aronoff; Michael J Germain; Michael E Brier
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

5.  Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis.

Authors:  Keiichi Sumida; Charles Dyer Diskin; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Connie M Rhee; Elani Streja; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Nephrol       Date:  2017-11-07       Impact factor: 3.754

6.  Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis.

Authors:  Juan José Pérez-Ruixo; Mercedes Cucala-Ramos; Ester García-Gonzalo; Beatriz Del Val Romero; Neus Valveny
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

7.  The effect of altitude on dosing and response to erythropoietin in ESRD.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Jerry Avorn; Brian D Bradbury; Kenneth J Rothman; Michael Fischer; Jyotsna Mehta; Wolfgang C Winkelmayer
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

8.  Cost of managing anemia in end-stage renal disease: the experience of five French dialysis centers.

Authors:  Jacques Rottembourg; Patrick Tilleul; Gilbert Deray; Antoine Lafuma; Lorraine Zakin; Lamine Mahi; Jorge Wernli
Journal:  Eur J Health Econ       Date:  2014-02-26

9.  Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness.

Authors:  Angel L M de Francisco; Peter Stenvinkel; Sophie Vaulont
Journal:  NDT Plus       Date:  2009-01

10.  Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.

Authors:  Silvia Soffritti; Giorgia Russo; Stefano Cantelli; Giuseppe Gilli; Luigi Catizone
Journal:  BMC Nephrol       Date:  2009-10-24       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.